PUT/NOVARTIS N/70/0.1/20.12.24 Share Price

Warrant

DE000GQ800H3

Market Closed - BOERSE MUENCHEN 19:27:18 03/07/2024 BST
0.033 EUR -2.94% Intraday chart for PUT/NOVARTIS N/70/0.1/20.12.24
1 month-10.81%
3 months-58.23%
Date Price Change
03/07/24 0.033 -2.94%
02/07/24 0.034 -2.86%
01/07/24 0.035 +2.94%
28/06/24 0.034 -2.86%
27/06/24 0.035 +6.06%

Real-time BOERSE MUENCHEN

Last update July 03, 2024 at 07:27 pm

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying NOVARTIS AG
Issuer Goldman Sachs
WKN GQ800H
ISINDE000GQ800H3
Date issued 24/10/2023
Strike 70 CHF
Maturity 20/12/2024 (170 Days)
Parity 10 : 1
Emission price 0.22
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.237
Lowest since issue 0.032
Delta-0.06x
Omega 9.817
Premium27.74x
Gearing173.39x
Moneyness 0.7283
Difference Strike -26.11 CHF
Difference Strike %-37.30%
Spread 0.05
Spread %60.98%
Theoretical value 0.0570
Implied Volatility 32.15 %
Total Loss Probability 91.39 %
Intrinsic value 0.000000
Present value 0.0570
Break even 69.45 €
Theta-0x
Vega0.01x
Rho-0x

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
-
More about the company

Ratings for Novartis AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Novartis AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
106.7 USD
Average target price
110.3 USD
Spread / Average Target
+3.41%
Consensus